International Journal of Phytomedicine and Phytotherapy
Table 3 Treatment indications (> 3%) (Safety Set)
HMP form | |||
|---|---|---|---|
Indication | Total | Oral solution | Tablets |
System Organ Class / Preferred Term | (N = 634) | (N = 421) | (N = 213) |
Infections and infestation | 475 (74.9%) | 326 (77.4%) | 149 (70.0%) |
Urinary tract infection | 216 (34.1%) | 171 (40.6%) | 45 (21.1%) |
Pyelonephritis chronica | 80 (12.6%) | 40 (9.5%) | 40 (18.8%) |
Cystitis | 72 (11.4%) | 39 (9.3%) | 33 (15.5%) |
Pyelonephritisa | 71 (11.2%) | 50 (11.9%) | 21 (9.9%) |
Pyelonephritis acutea | 39 (6.2%) | 29 (6.9%) | 10 (4.7%) |
Renal and urinary disorders | 225 (35.5%) | 136 (32.3%) | 89 (41.8%) |
Hyperoxaluria | 106 (16.7%) | 73 (17.3%) | 33 (15.5%) |
Hypercalciuria | 31 (4.9%) | 20 (4.8%) | 11 (5.2%) |
Calculus urinary | 23 (3.6%) | 12 (2.9%) | 11 (5.2%) |
Haematuria | 23 (3.6%) | 15 (3.6%) | 8 (3.8%) |